Skip to main content

Department

Referred Work
INFLIX

Preferred Sample Type

Infliximab drug monitoring

Suitable Specimen Types

  • Serum
  • Li Hep
Minimum of 300uL of serum or plasma for both drug and anti drug antibody analysis

Specimen Transport

Sample sent via post to referral laboratory

Sample Processing in Laboratory

Sample separated and sent to referral laboratory

Sample Preparation

Sample collected into SST tube or Lithium Heparin tube

Turnaround Time

3 weeks

Sample Stability

Stable at 4C, If transport is going to be delayed by > 5 days, freeze at -20°C and send by first class post at a later date.

Infliximab drug monitoring

General Information

Measurement of Infliximab is a useful tool in the management of patients who fail to respond ( primary failure) or lose response ( secondary failure) to treatment. Monitoring drug levels allows for a personalised approach to drug optimisation by appropriate dose escalation/de-escalation or drug switching/withdrawal. Measured as part of Infliximab profile which includes anti drug antibodies. Assay also measures biosimilars Remsima and Inflectra. Specific request form is required for this assay download from: http://www.viapath.co.uk/sites/default/files/upload/News/Anti-TNF%20request%20formv6.pdf

Patient Preparation

No specific preparation required.

Notes

Infliximab is a chimeric (mouse-human) monoclonal antibody which specifically targets tumour necrosis factor alpha (TNFα). Infliximab is licensed for use in Gastroenterology (Crohn's diseases, ulcerative colitis), Rheumatology (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis) and Dermatology (sever plaque psoriasis). Infliximab is only indicated in patients with severe disease which is refractory to conventional therapeutic approaches.

Reference Range

Please use drug levels as a guide. Infliximab Interpretation: Therapeutic drug levels: >2 µg/mL Intermediate drug levels: 1.0 – 2.0 µg/mL Subtherapeutic drug levels: < 1.0 µg/mL Test interpretation requires full clinical information: drug dosage/frequency, previous exposure to other biologics, time of sampling, duration of therapy and clinical assessment.

Source of Reference Range

Supplied by reference laboratory

Specifications

  • EQA Scheme?: No
  • EQA Status: No EQA scheme available.